New survival data from the MIRASOL trial support the use of this antibody-drug conjugate as a preferred standard of care for patients with high folate receptor alpha tumour expression
While updated results from the DUO-O trial appear promising, they are not conclusive due to the study design
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.